daclizumab

(redirected from Dacliximab)

daclizumab

 [dah-kliz´u-mab]
an immunosuppressant used to prevent acute organ rejection in renal transplant patients; administered intravenously.

daclizumab

/da·cliz·u·mab/ (dah-kliz´u-mab) an immunosuppressant used to prevent acute organ rejection in renal transplant patients.

daclizumab

an immunosuppressant.
indications It is used to help prevent acute allograft rejection in renal transplant patients.
contraindications Known hypersensitivity to this drug contraindicates its use.
adverse effects Life-threatening effects are pulmonary edema, tachycardia, thrombosis, renal tubular necrosis, and hydronephrosis. Other adverse effects include headache, prickly sensation, coughing, atelectasis, congestion, constipation, abdominal pain, pyrosis, hypertension, bleeding, oliguria, dysuria, renal damage, and impaired wound healing. Common side effects include chills, tremors, dyspnea, wheezing, vomiting, nausea, and diarrhea.

daclizumab

Dacliximab, Zenapax® Transplant medicine A monoclonal antibody used with other agents to ↓ transplant-related GVHD and organ rejection in kidney and liver graft recipients, and Pts with treatment refractory psoriasis, uveitis, tropical spastic paraparesis and some leukemias. See Kidney transplant.

daclizumab

A humanized monoclonal antibody against the interleukin-2 receptor. It is used to decrease the risk of organ rejection in kidney and heart transplants.
References in periodicals archive ?